植入性缓释给药系统在青光眼治疗中的应用

Application of implantable sustained release drug delivery system on glaucoma treatment

青光眼发病的影响因素较多,目前眼压仍然是唯一可控因素。药物疗法以常规滴眼液局部给药为主,但其存在药物生物利用度低、患者用药方法不当及依从性低等问题。近年来,药物缓释系统(drug delivery system,DDS)持续进展,有望解决上述问题。植入性DDS可分为可降解型和不可降解型,可使药物在眼内的有效浓度保持较长时间,尤为适用于需要长期治疗的眼部疾病。近年来有5个新青光眼药物缓释装置(贝美前列素持续释放植入物、曲伏前列素延长释放植入物ENV515、曲伏前列素植入物iDose、曲伏前列素泪点栓、拉坦前列素泪点栓系统)投入临床试验。

There are many factors affecting the incidence of glaucoma,and intraocular pressure is still the only controllable factor.Drug therapy is mainly based on topical administration of conventional eye drops.This method has certain shortcomings,including the low bioavailability of the drug,the uncorrect medication of the patient and the low compliance.In recent years,the continuous development of drug delivery system(DDS)has made it possible to successfully solve the above problems.Implantable DDS can be divided into degradable type and non-degradable type,which can keep the effective concentration of the drug in the eye for a long time,and is especially suitable for eye diseases that require long-term treatment.In recent years,a total of 5 new glaucoma drug slow-release devices including bimatoprost SR,ENV515,iDose,OTX-TP,L-PPDS have been put into clinical trials.